

## **Publikationen** (inkl. der bereits im Hauptdokument genannten)

### **2.1. Originalarbeiten**

1. M. Karl, **G von Wichert**, E. Kempter, D.A. Katz, M. Reincke, H. Mönig, I.U. Ali, C.A. Stratakis, E.H. Oldfield, G.P. Chrousos and H.M. Schulte Nelson's syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene 1996, J. Clin. Endocrinol Metab. 81: 124-9
2. **G von Wichert**, P.M. Jehle, A. Hoeflich, S. Koschnick, H. Dralle, E. Wolf, B. Wiedenmann, B.O. Boehm, Guido Adler and Thomas Seufferlein, Insulin-like growth factor-I is an autocrine regulator of chromogranin A secretion and growth in human neuroendocrine tumor cells 2000, Cancer Res. 60: 4573-81
3. T. Seufferlein, M.J. Seckl, E. Schwarz, M. Beil, **G von Wichert**, H. Baust, H. Lührs, R.M. Schmid and G. Adler Mechanisms of nordihydroguaiaretic acid-induced growth inhibition and apoptosis in human cancer cells 2002, Br. J. Cancer 86: 1188-96
4. **G von Wichert**, G. Jiang, A. Kostic, K. De Vos, J. Sap and M.P. Sheetz, RPTP-alpha acts as a transducer of mechanical force on  $\alpha_v/\beta_3$ -integrin-cytoskeleton linkages 2003, J. Cell Biol. 161: 143-153
5. M. Beil, A. Micoulet, **G von Wichert**, S. Paschke, P. Walter, B. Omary, P. van Veldhoven, U. Gern, E. Wolff-Hieber, J. Eggermann, J. Waltenberger, G. Adler, J. Spatz and T. Seufferlein, Shingosylphosphorylcholine regulates the keratin cytoskeleton and cellular viscoelasticity of human epithelial tumor cells 2003, Nat. Cell Biol. 9: 803-11
6. **G von Wichert**, G.S. Feng and M.P. Sheetz, Force dependent establishment of integrin-cytoskeleton linkages requires downregulation of focal contact dynamics by Shp2 2003, Embo J. 22: 5023-35
7. **G von Wichert**, U. Haeussler, F.R. Greten, S. Kliche, H. Dralle, B.O. Böhm, G. Adler and T. Seufferlein, Regulation of cyclin D1 expression by autocrine IGF-I in human BON neuroendocrine tumor cells 2005, Oncogene 24:1284-89
8. U. Haeussler, **G von Wichert**, R. M. Schmid, F. Keller and G. Schneider, Epidermal Growth Factor (EGF) activates nuclear factor B in human proximal tubule cells 2005, Am. J. Physiol. renal, 289: 808-15

9. A. Auer, J. von Blume, S Sturany, **G von Wichert**, J. van Lint, J. Vandenheede, G. Adler and T. Seufferlein Role of the regulatory domain of protein kinase D2 in phorbol ester binding, catalytic activity and nucleocytoplasmic shuttling 2005, *Mol. Biol. Cell*, 16:4375-85
10. K. Jungert, A. Buck, G. Adler, **G von Wichert**, T. M. Gress, V. Ellenrieder Sp1 is required for TGF $\beta$  induced transcriptional induction of mesenchymal transition and migration in pancreatic cancer cells 2007, *Cancer Res*: 67:1563-70
11. T. Aleksic, **G von Wichert**, K. Giehl, T.M. Gress, P. Michl CUTL1 promotes tumor cell migration by decreasing proteasome-mediated Src degradation 2007, *Oncogene*: 26(40): 5939-49
12. B. Baumann, M. Wagner, T. Aleksic, **G von Wichert**, CK. Weber, G. Adler, T. Wirth. Constitutive IKK2 activation in acinar cells is sufficient to induce pancreatitis in vivo. 2007, *J Clin Invest*: 117:1502-13.
13. **G von Wichert**, D. Krndija, H. Schmid, G. von Wichert, G. Haerter, G. Adler, T. Seufferlein, M. P. Sheetz Focal Adhesion Kinase mediates defects in the force-dependent reinforcement of initial integrin-cytoskeleton linkages in metastatic colon cancer cell lines 2008, *E J Cell Biol*: 87(1):1-16
14. **G von Wichert**, T. Edenfeld, J. von Blume, H. Krisp, D. Krndija, H. Schmid, F. Oswald, P. Walther, G. Adler, T. Seufferlein Protein kinase D2 regulates chromogranin A secretion in human BON neuroendocrine tumour cells 2008 *Cell Signal*: 20(5):925-34
15. V. Kächele, **G von Wichert**, G. Adler, T. Seufferlein Response to the reintroduction of cetuximab in patients with advanced, chemotherapy-resistant colorectal cancers without progress during first-line application of the antibody 2008, *Oncology* 74:123-126.
16. D. Krndija, H. Schmid, J. Eismann, U. Lothar, G. Adler, F. Oswald, T. Seufferlein, **G von Wichert** Substrate stiffness and the receptor-type tyrosine-protein phosphatase alpha (RTP $\alpha$ ) regulate spreading of colon cancer cells via cytoskeletal contractility 2010, *Oncogene* 6;29(18):2724-38
17. G. V. Pusapati, D. Krndija, M. Armacki, **G von Wichert**, J. von Blume, V. Malhotra, G. Adler, T. Seufferlein Role of the second cysteine-rich domain and Pro275 in PKD2 interaction with ARF1, TGN recruitment and protein transport 2010 *Mol Biol Cell* (6):1011-22.
18. V. Kaechele, M. Moehler, MP. Lutz, **G von Wichert**, M. Eisele, J. Klaus, PR. Galle, G. Adler, T. Seufferlein A phase I/II study of oxaliplatin and paclitaxel in patients with non-resectable cancer of the oesophagus and adenocarcinoma of the gastro oesophageal junction: A Study of the Arbeitsgemeinschaft Internistische Onkologie 2010 *Cancer Chemother Pharmacol*. 66 (1) : 191-5
19. J. Huth, M. Buchholz, M. Schmucker, **G von Wichert**, D. Krndija, T. Seufferlein, T.M. Gress, H. A. Kestler Cell migration analysis in time lapse imaging – automated vs manual tracking 2010 *BMC Cell Biol*.;11:24.

20. S. A. Wacker, C. Alvarado, **G von Wichert**, U. Knippschild, J. Wiedenmann, K. Clauß, G. Nienhaus, H. Hameister, B. Baumann, T. Borggreffe, W. Knöchel, F. Oswald RITA/C12ORF52, a novel modulator of Notch signalling, acts via nuclear export of RBP-J 2011 *Embo J* 30 (1) 43-56.
21. M Müller, M Stockmann, D Malan, A Wolheim, M Tischendorf, L Linta, SF Katz, Q Lin, S Latz, C Brunner, AM Wobus, M Zenke, M Wartenberg, TM Boeckers, **G von Wichert**, BK Fleischmann, S Liebau, A Kleger. Ca<sup>2+</sup> Activated K Channels-New Tools to Induce Cardiac Commitment from Pluripotent Stem Cells in Mice and Men. *Stem Cell Rev.* 2011 Oct 26. Epub
22. S Liebau, M Tischendorf, D Ansorge, L Linta, M Stockmann, C Weidgang, M Iacovino, TM Boeckers, **G von Wichert**, M Kyba, A Kleger An inducible expression system of the calcium-activated potassium channel 4 to study the differential impact on embryonic stem cells. *Stem Cells Int.* 2011:456815
23. J. Huth, M. Buchholz, J. M. Kraus, K. Mølhave, C. Gradinaru, **G. von Wichert**, T. M. Gress, H. Neumann, H. A. Kestler TimeLapseAnalyser: Multi-target analysis for live-cell imaging and time-lapse microscopy. 2011 *Comput Methods Programs Biomed*;104(2): 227-34.
24. T Busch, J. Jansen, **G von Wichert**, H. Frank, B. Omary, G. Adler, T. Seufferlein Role of keratin 8 serine phosphorylation in keratin reorganization and migration of epithelial tumor cells 2012 *J Cell Science* 125(Pt 9):2148-59
25. G. Pusapati, A. Rykx, S. Vandoninck, R. Derua, J. Van Lint†, **G. von Wichert**, Thomas Seufferlein Protein kinase D regulates RhoA activity via rhotekin phosphorylation. 2012 *J Biol Chem* 287(12):9473-83.
26. D. Krndija, H. Schmid, H Kestler, G. Adler, F. Oswald, **G von Wichert** Phosphatase of regenerating liver binds to and activates ARF 1 and regulates migration via enhanced recycling of alpha 5 integrins 2012 *J Cell Science* May 17. [Epub ahead of print]
27. Rahbari NN, Lordick F, Fink C, Bork U, Stange A, Jäger D, Luntz SP, Englert S, Rossion I, Koch M, Büchler MW, Kieser M, Weitz J; SYNCHRONOUS trial group. Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555). *BMC Cancer.* 2012 Apr 5;12:142.
28. CC Schimanski, M. Mohler, M. Schon, E. van Cutsem, R. Greil, W. Bechstein, S. Hegewisch-Becker, **G. von Wichert**, M. Vohringer, M. Heike, V. Heinemann, M. Peeters, S. Kanzler, S. Kasper, F. Overkamp, H. Samonigg, D. Seehofer, F. Kullmann, I. Schmidtman, V. Smith-Machnow, I. Gockel, H. Lang, P.R Galle LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases--a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trial 2012 *BMC Cancer*, 12:144
29. G Fois, M Weimer, T Busch, ET Felder, F Oswald, **G von Wichert**, T Seufferlein, P Dietl, E Felder Effects of keratin phosphorylation on the mechanical properties of keratin filaments in living cells. *FASEB J.* 2012 Dec 14. [Epub ahead of print]

30. C Villinger, H Gregorius, C Kranz, K Höhn, C Münzberg, **G von Wichert**, B Mizaikoff, G Wanner, P Walther FIB/SEM tomography with TEM-like resolution for 3D imaging of high-pressure frozen cells. *Histochem Cell Biol.* 2012 Oct;138(4):549-56

31. Bennouna J, Sastre J, Arnold D, Österlund P, Greil R, Van Cutsem E, von Moos R, Viéitez JM, Bouché O, Borg C, Steffens CC, Alonso-Orduña V, Schlichting C, Reyes-Rivera I, Bendahmane B, André T, Kubicka S; ML18147 Study Investigators. (Andel J, Balcke P, Benedicic B, Eisterer W, Fridrik M, Jagdt B, Keil F, Kretschmer A, Krippel P, Oexle H, Pecherstorfer M, Samonigg H, Schmid M, Thaler J, Tinchon C, Weiss H, Arts J, De Man M, Demolin G, Janssens J, Polus M, Benczikova B, Melichar B, Prausova J, Vitek P, Andersen FZ, Jensen BB, Keldsen N, Østerlind K, Vistisen K, Elme A, Magi A, Ojamaa K, Ristamäki R, Salminen T, Ben Abdelghani M, Bouhier-Leporrier K, Breysacher G, Chone L, Clavero Fabri MC, Deplanque G, Desseigne F, Dourthe LM, Ezenfis J, Faroux R, François E, Garnier C, Gaspard MH, Hebbbar M, Illory JF, Kaminsky MC, Lecomte T, Legoux JL, Levache B, Lobry C, Lotz JP, Mabro M, Manet-Lacombe S, Manfredi S, Matysiak Budnik T, Miglianico L, Mineur L, Moullet I, Naman H, Nouyrigat P, Oziel-Taieb S, Perrier H, Pezet D, Philip J, Pottier V, Porneuf M, Ramdani M, Re D, Rinaldi Y, Spaeth D, Taieb J, Terrebonne E, Texereau P, Thiot BA, Tournigand C, Tubiana-Mathieu N, Vantelon JM, Viret F, Ychou M, Bangerter M, Bertram ME, Bohnsteen B, Brinkmann L, Caca K, Constantin C, Cordes H, Dietrich G, Eggert J, Engel E, Fahlke J, Fensterer H, Florschütz A, Folprecht G, Forstbauer H, Freier W, Freund M, Frickhofen N, Gäbele E, Geißler M, Gieseler F, Göhler T, Graeven U, Groschek M, Grundeis M, Hacker U, Hagen V, Hebart HF, Hegewisch-Becker S, Heike M, Herrmann T, Hildebrandt B, Höffkes HG, Hübner G, Hübner J, Kettner E, Kneba M, Kohnke JW, Kojouharoff G, König C, Kretschmar A, Kröning H, Kürner K, Lammert F, Lerchenmüller C, Lück A, Meiler J, Mergenthaler HG, Müller L, Müller-Naendrup C, Nusch A, Papke J, Porschen R, Rädle J, Reddemann C, Ridwelski K, Riera-Knorrenschild J, Rudi J, Schmalenberger A, Schimanski CC, Schlegel F, Schmidt P, Schmiegel W, Schmitz S, Schulze-Bergkamen H, Schwaner I, Schwarzer A, Schwerdtfeger M, Selbach J, Sieber M, Siebler J, Staib P, Stauch M, Stübs P, Tischendorf J, Trarbach T, Tummes D, Valdex AR, Vogel A, **G von Wichert**, Walther M, Welslau W, Wilhelm G, Wobster H, Wolf T, Zeigenhagen N, Zomorodbaksch B, Batman E, Bloemendal HJ, Kehrer DF, Guren T, Indrebø G, Kersten C, Sorbye H, Fragoso M, Fragoso R, Mellidez JC, Sa A, Aljobran A, Darwish T, Aparicio J, Aranda E, Bosch C, Galan-Brotos A, Busquier Hernandez I, Camara JC, Campos Cervera JM, Carlos Garcia Giron C, Del Prado PM, Donnay O, Escudero P, Falco E, Gallego Plazas J, Garcia Alfonso P, Gonzalez Flores E, Gravalos C, Guardeno R, Juárez A, Lopez Ladron A, Losa Gaspa F, Ma Vicent Vergé J, Marcuello Gaspar E, Massuti Sureda B, Molina J, Montero IC, Muñoa AL, Naranjo MB, Oruezabal Moreno MJ, Pachón Olmos V, Pericay C, Reina Zoilo JJ, Rivera F, Ruiz Casado A, Safont MJ, Salud Salvia A, Tobena M, Toral JC, Valenti V, Valladares Ayerbes M, Vera R, Berglund A, Fernebro E, Hess-Umbricht V, Pless M, Popescu R, Winterhalder R) Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. *Lancet Oncol.* 2013 Jan;14(1):29-37.

32. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Melezínková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators. (Fein L, Troon S, Cosolo W, Zabernigg A, Andel J, van Laethem JL, Kalantari HR, D'Haens G, Sasse AD, Hélio P, Franke FA, Fanelli MF, Coutinho AK, Beato C, Barrios CH, Tomova A, Kurteva G, Ivanova N, Guenova K, Acevedo A, Yanez E, Soto L, Salman P, Gallardo J, Loredó E, Li J, Wang Y, Qin SK, Liu Y, Guan Z, Sun Y, Shen L, Xu JM, Hefei JM, Chen Z, Prausova J,

Petera J, Bencsikova B, Seitz JF, Raoul JL, Pezet D, Faroux R, Deplanque G, Borg C, Pavlidis N, Fountzilas G, Zoller W, Ziske C, Wilke H, Trarbach T, **G von Wichert**, Weissinger F, Weihrauch M, Schepp W, Karthaus M, Heinemann V, Dechow T, Sahm S, Kullmann F, Moehler M, Lordick F, Lorenzen S, Kleinschmidt R, Cordes HJ, Kanzler S, Dresden S, Illmer H, Folprecht G, Hoffmann M, Hegewisch-Becker S, Geissler M, Geer T, Endlicher E, Daum S, Lo SH, Chu KM, Pintér T, Pécsi B, Osváth M, Dank M, Bodoky G, Bittner N, Shulman K, Shmueli-Shaham E, Brenner B, Aderka D, Hubert A, Ciardiello F, Cascinu S, Siena S, Santoro A, Martoni A, Barone C, Hironaka S, Fuse N, Yamaguchi K, Sasaki Y, Yamada Y, Omuro Y, Tsuburaya A, Takiuchi H, Satoh T, Sawaki A, Nishina T, Komatsu Y, Hamamoto Y, Fujii H, Chin K, Boku N, Staroslawska E, Pikiel J, Jassem J, Filipczyk-Cisarz E, Drosik K, Araujo A, Volovat C, Niculescu A, Filip D, Croitoru AE, Cebotaru C, Moiseyenko VM, Karaseva N, Khasanov R, Gorbunova V, Borisov V, Berdov B, Zang DY, Shin BD, Oh SC, Kim YH, Kim TY, Kang YK, Park JO, Chung HC, Lee KW, Kim JG, Safont MJ, Molins C, Rodríguez J, Rivera F, Quintero G, Marin M, Limón ML, Yeh KH, Jung-Tainan Y, Tsao C, Hsieh JS, Chen YY, Chiu CF, Chen JS, Chang CS, Mansoor AW, Middleton G. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. *Lancet Oncol.* 2013 May; 14(6):490-9.

33. Combination of antiangiogenic therapy using the mTOR-inhibitor everolimus and low-dose chemotherapy for locally advanced and/or metastatic pancreatic cancer: a dose-finding study. Joka M, Boeck S, Zech CJ, Seufferlein T, **G von Wichert**, Licht T, Krause A, Jauch KW, Heinemann V, Bruns CJ. *Anticancer Drugs.* 2014 Oct;25(9):1095-101

34. Kuehnle MC, Attig S, Britten CM, Schulze-Bergkamen H, Lordick F, **G von Wichert**, Thuss-Patience P, Stein A, Schuler M, Bassermann F, Sahin U, Türeci O. Phenotyping of peripheral blood mononuclear cells of patients with advanced heavily pre-treated adenocarcinoma of the stomach and gastro-esophageal junction. *Cancer Immunol Immunother.* 2014 Dec;63(12):1273-84

35. Kubicka S, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D; ML18147 study investigators including AIO, GERCOR, FFCD, UNICANCER GI, TTD, BGDO, GEMCAD, and AGMT groups. (Andel J, Balcke P, Benedicic B, Eisterer W, Fridrik M, Jagdt B, Keil F, Kretschmer A, Krippel P, Oexle H, Pecherstorfer M, Samonigg H, Schmid M, Thaler J, Tinchon C, Weiss H, Arts J, De Man M, Demolin G, Janssens J, Polus M, Benczikova B, Melichar B, Prausova J, Vitek P, Andersen F, Jensen B, Keldsen N, Osterlind K, Vistisen K, Elme A, Magi A, Ojamaa K, Ristamäki R, Salminen T, Ben Abdelghani M, Bouche O, Borg C, Bouhier-Leporrier K, Breysacher G, Chone L, Clavero Fabri MC, Deplanque G, Desseigne F, Dourthe LM, Ezenfis J, Faroux R, François E, Garnier C, Gaspard MH, Hebbar M, Illory J, Kaminsky MC, Lecomte T, Legoux JL, Levache B, Lobry C, Lotz JP, Mabro M, Manet-Lacombe S, Manfredi S, Matysiak Budnik T, Miglianico L, Mineur L, Moullet I, Naman H, Nouyrigat P, Oziel-Taieb S, Perrier H, Pezet D, Philip J, Pottier V, Porneuf M, Ramdani M, Re D, Rinaldi Y, Spaeth D, Taieb J, Terrebonne E, Texereau P, Thiroit Bidault A, Tournigand C, Tubiana-Mathieu N, Vantelon JM, Viret F, Ychou M, Bangerter M, Bertram M, Bohnsteen B, Brinkmann L, Caca K, Constantin C, Cordes HJ, Dietrich G, Eggert J, Engel E, Fahlke J, Fensterer H, Florschütz A, Folprecht G, Forstbauer H, Freier W, Freund M, Frickhofen N, Gäbele E, Geißler M, Gieseler F, Göhler T, Graeven U, Groschek M, Grundeis M, Hacker U, Hagen V, Hebart H, Hegewisch-Becker S, Heike M, Herrmann T, Hildebrandt B, Höffkes HG, Hübner G, Hübner J, Kettner E, Kneba M, Kohnke J, Kojouharoff G, König C, Kretschmar A, Kröning H, Kürner

K, Lammert F, Lerchenmüller C, Lück A, Meiler J, Mergenthaler HG, Müller L, Müller-Naendrup C, Nusch A, Papke J, Porschen R, Rädle J, Reddemann C, Ridwelski K, Riera-Knorrenschild J, Rudi J, Schmalenberger A, Schimanski CC, Schlegel F, Schlichting C, Schmidt P, Schmiegel W, Schmitz S, Schulze-Bergkamen H, Schwaner I, Schwarzer A, Schwerdtfeger M, Selbach J, Sieber M, Siebler J, Staib P, Stauch M, Steffens CC, Stübs P, Tischendorf J, Trarbach T, Tummes D, Valdix AR, Vogel A, **G von Wichert**, Walther M, Welslau W, Wilhelm G, Wobster H, Wolf T, Zeigenhagen N, Zomorodbaksch B, Batman E, Bloemendal H, Kehrer D, Guren T, Indrebø G, Kersten C, Soerbye H, Fragoso M, Fragoso R, Mellidez J, Sa A, Aljobran A, Darwish T, Alonso-Orduna V, Aparicio J, Aranda E, Bosch C, Galan-Brotos A, Busquier Hernandez I, Camara J, Campos Cervera J, Carlos Garcia Giron C, Del Prado P, Donnay O, Escudero P, Falco E, Gallego Plazas J, Garcia Alfonso P, Gonzalez Flores E, Gravalos C, Guardeno R, Juárez A, Lopez Ladron A, Losa Gaspa F, M Vicent Vergé J, Marcuello Gaspar E, Massuti Sureda B, Molina J, Montero I, Muñoa A, Naranjo M, Oruezabal Moreno M, Pachón Olmos V, Pericay C, Reina Zoilo J, Rivera F, Ruiz Casado A, Safont M, Salud Salvia A, Tobena M, Toral J, Valenti V, Valladares Ayerbes M, Vieitez J, Vera R, Vieitez J, Berglund A, Fernebro E, Hess-Umbricht V, Pless M, Popescu R, Winterhalder R.) Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. *Ann Oncol.* 2013 Sep;24(9):2342-9. doi: 10.1093/annonc/mdt231. Epub 2013 Jul 12.

36. Hoehler T, **G von Wichert**, Schimanski C, Kanzler S, Moehler MH, Hinke A, Seufferlein T, Siebler J, Hochhaus A, Arnold D, Hallek M, Hofheinz R, Hacker UT. Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205. *Br J Cancer.* 2013 Sep 17;109(6):1408-13.

37. Taieb J1, Tabernero J2, Mini E3, Subtil F4, Folprecht G5, Van Laethem JL6, Thaler J7, Bridgewater J8, Petersen LN9, Blons H10, Collette L11, Van Cutsem E12, Rougier P13, Salazar R14, Bedenne L15, Emile JF16, Laurent-Puig P17, Lepage C15; PETACC-8 Study Investigators (Thaler J, Greil R, Gaenzler J, Eisterer W, Tschmelitsch J, Keil F, Samonigg H, Zubernig A, Schmid F, Steger G, Steinacher R, Andel J, Jagdt B, Lang A, Fridrik M, Függer R, Hofbauer F, Woell E, Geissler D, Lenauer A, Prager M, D'Haens G, Kerger J, Deboever G, Ghillebert G, Polus M, Van Cutsem E, Kalantari HR, Delaunoit T, Goeminne JC, Peters M, Vergauwe P, Houbiers G, Humblet Y, Janssens J, Schrijvers D, Vanderstraeten E, Van Laethem JL, Vermorken J, Van Daele D, Ferrante M, Forget F, Hendlitz A, Yilmaz M, Nielsen SE, Vestermark L, Larsen J, Zawadi MA, Bouche O, Mineur L, Bennouna-Louridi J, Dourthe LM, Ychou M, Boucher E, Taieb J, Pezet D, Desseigne F, Ducreux M, Texereau P, Miglianico L, Rougier P, Fratte S, Levache CB, Merrouche Y, Ellis S, Locher C, Ramee JF, Garnier C, Viret F, Chauffert B, Cojean-Zelek I, Michel P, Lecaillon C, Borel C, Seitz JF, Smith D, Lombard-Bohas C, Andre T, Gornet JM, Fein F, Coulon-Sfairi MA, Kaminsky MC, Lagasse JP, Luet D, Etienne PL, Gasmi M, Vanoli A, Nguyen S, Lobry C, Perrier H, Stremmsdoerfer N, Laplaige P, Arsene D, Auby D, Bedenne L, Cochin P, Denis B, Geoffroy P, Piot G, Becouarn Y, Bordes G, Deplanque G, Dupuis O, Fruge F, Guimbaud R, Lecomte T, Lledo G, Sobhani I, Asnacios C, Azzedine A, Desauw C, Galais MP, Gargot D, Lam YH, Abakar-Mahamat A, Berdah JF, Catteau S, Clavero-Fabri MC, Codoul JF, De Ledinghen V, Goldfain D, Guichard P, Verge DP, Provencal J, Provencal J, Vedrenne B, Brezault-Bonnet C, Cleau D, Desir JP, Fallik D, Garcia B, Gaspard MH, Genet D, Hartwig J, Krummel Y, Budnik TM, Palascak-Juif V, Randrianarivelo H, Rinaldi Y, Aleba A, Darut-Jouve A, Hamon H, Wendehenne F, Matzdorff A, Stahl MK, Schepp W, Burk M, Mueller L, Folprecht G, Geissler M, Mantovani-Loeffler L, Hoehler T, Asperger W, Asperger W, Kroening H, von Weikersthal LF, Fuxius S, Groschek M,

Meiler J, Trarbach T, Rauh J, Ziegenhagen N, Kretzchmar A, Graeven U, Nusch A, **G von Wichert**, Hofheinz RD, Kleber G, Schmidt KH, Vehling-Kaiser U, Baum C, Schuette J, Haag GM, Holtkamp W, Potenberg J, Reiber T, Schliesser G, Schmoll HJ, Schneider-Kappus W, Abenhardt W, Denzlinger C, Henning J, Derigs HG, Lambertz H, Ingulf BB, Caca K, Constantin C, Decker T, Eschenburg H, Gabius S, Hebart H, Hoffmeister A, Heinz-August H, Kremers S, Leithaeuser M, Mueller S, Wagner S, Daum S, Schlegel F, Stauch M, Heinemann V, Maiello E, Latini L, Zaniboni A, Amadori D, Aprile G, Barni S, Mattioli R, Martoni A, Passalacqua R, Nicolini M, Pasquini E, Rabbi C, Aitini E, Ravaioli A, Barone C, Biasco G, Tamberi S, Gambi A, Verusio C, Marzola M, Lelli G, Boni C, Cascinu S, Bidoli P, Vaghi M, Cruciani G, Di Costanzo F, Sobrero A, Mini E, Petrioli R, Aglietta M, Alabiso O, Capuzzo F, Falcone A, Corsi DC, Labianca R, Salvagni S, Chiara S, Ciuffreda L, Ferraù F, Vincenzo T, Giuliani F, Lonardi S, Gebbia N, Mantovani G, Sanches E, Mellidez JC, Santos P, Freire J, Sarmento C, Costa L, Pinto AM, Barroso S, Santo JE, Guedes F, Monteiro A, Sa A, Furtado I, Salazar R, Aguilar EA, Herrero FR, Tabernero J, Valera JS, Ayerbes MV, Batlle AF, Gil S, Esteve AA, Garcia-Giron C, Vivanco GL, Salvia AS, Orduña VA, Garcia RV, Gallego J, Sureda BM, Remon J, Aguilera MJ, Nogueras LC, Merino BQ, Merino BQ, Castro CG, Martinez de Prado P, Pijaume Pericay C, Constenla Figueiras M, Guasch Jordan I, Gome Reina MJ, Lopez-Ladron Garcia A, Garcia-Ramos AA, Cervantes A, Fernandez Martos C, Marcuello Gaspar E, Cabezas Montero I, Escudero Emperador P, Leon Carbonero A, Gallen Castillo M, Garcia Garcia T, Garcia Lopez J, Gonzalez Flores E, Guillot Morales M, Llanos Muñoz M, López Martín A, Maurel J, Camara JC, Dueñas Garcia R, Salgado M, Hernandez Busquier I, Checa Ruiz T, Lacasta Muñoz A, Nogue Aliguer M, Ortiz de Taranco AV, Mendez Ureña M, Losa Gaspa F, Ponce JJ, Bosch Roig C, Valero Jimenez P, Galan Brotons A, Albiol Rodriguez S, Ales Martinez J, Canosa Ruiz L, Centelles Ruiz M, Bridgewater J, Glynn-Jones R, Tahir S, Hickish T, Cassidy J, Samuel L.) Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncol.* 2014 Jul;15(8):862-73.

38 Münzberg C, Höhn K, Krndija D, Maaß U, Bartsch DK, Slater EP, Oswald F, Walther P, Seufferlein T, **G von Wichert**. IGF-1 drives chromogranin A secretion via activation of Arf1 in human neuroendocrine tumour cells. *J Cell Mol Med.* 2015 May;19(5):948-59. doi: 10.1111/jcmm.12473.

39. Qin R, Schmid H, Münzberg C, Maass U, Krndija D, Adler G, Seufferlein T, Liedert A, Ignatius A, Oswald F, Eiseler T, **G von Wichert**. Phosphorylation and turnover of paxillin in focal contacts is controlled by force and defines the dynamic state of the adhesion site. *Cytoskeleton (Hoboken).* 2015 Feb;72(2):101-12.

40. Ettrich TJ, Perkhofer L, **G von Wichert**, Gress TM, Michl P, Hebart HF, Büchner-Stuedel P, Geissler M, Muche R, Danner B, Kächele V, Berger AW, Güthle M, Seufferlein T DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma. *BMC Cancer.* 2016;16(1):21.

41. Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators (**G von Wichert**); Austrian Breast and Colorectal cancer Study Group (ABCSSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en

Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater. Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23.

## 2.2. Übersichtsartikel und Kasuistiken

1. **G von Wichert** and M.P. Sheetz The biophysical interpretation of the ECM affects physiological and patho-physiological cellular behavior 2005; Z. Gastroenterol.,43:1329-1336
2. **G von Wichert** und P. von Wichert Möglichkeiten und Probleme der Applikation von systemisch wirksamen, höhermolekularen Wirkstoffen mittels Inhalation 2006, Med. Klin: 101(9):718-23
3. T Seufferlein, **G von Wichert**, G Adler. Palliative treatment of pancreatic cancer Dtsch Med Wochenschr. 2007;132:813-7
4. T Seufferlein, **G von Wichert**, G Adler Medikamentöse Therapie des Kolonkarzinoms Dtsch Med Wochenschr 2007: 132(38):1951-62
5. **G von Wichert**, T Seufferlein Adjuvante Chemotherapie bei soliden Tumoren des Gastrointestinaltraktes - sind Fortschritte erkennbar? Internist: 2007 48(12):1335-1342
6. T. Seufferlein, **G von Wichert**, G. Adler Diagnostik und Therapie des Pankreaskarzinoms Pharma Fokus Onkologie. 2007: 4; 12: 2-5
7. **G von Wichert**, T Seufferlein, G. Adler Palliative treatment of pancreatic cancer? 2008 *J. Dig. Dis.*: 9(1):1-7.
8. **G von Wichert**, G. Adler, T. Seufferlein Die Therapie des kolorektalen Karzinoms Tumordiagnostik & Therapie 2008, 03: (29); 134-139
9. **G von Wichert**, G. Adler, T. Seufferlein Die Prävention des kolorektalen Karzinoms Tumordiagnostik & Therapie 2008, 03: (29); 128-132
10. T. Seufferlein, J. Ahn, D. Krndija, U. Lothar, G. Adler, **G von Wichert** Tumor biology and cancer therapy - an evolving relationship. Cell Commun Signal. 2009 13; 7:19.
11. S. Walter, G. Adler, **G von Wichert** Kolonkarzinom: Einfluss der Ernährung sowie Prävention und Diagnostik Pharma Fokus Onkologie. 2009; 6: 12: 15-20



12. J. Stephani, G. Adler, **G von Wichert** Aktuelle Therapie der Gicht Gastroenterologie up2date 2010; 6(1): 63-78

13. **G von Wichert**, G. Adler, T Seufferlein Der Weg in die personalisierte Therapie von gastrointestinalen Tumorerkrankungen - Möglichkeiten und Limitationen, Dtsch Med Wochenschr 2010; 135(34-35):1687-91

14. S Walter, G Adler, **G von Wichert** Magenkarzinom: Aktuelles zu Diagnose und Therapie Pharma Fokus Onkologie. 2010; 7: 18 -24

15. K Giehl, M Bachem, M Beil, BO Bohm, VEllenrieder, SFulda, TM Gress, K Holzmann, HA Kestler, M Kornmann, AMenke, PMoeller, F Oswald, RM Schmid, V Schmidt, R Schirmbeck, T Seufferlein, **G von Wichert**, M Wagner, P Walther, T Wirth, G Adler Inflammation, Regeneration and Transformation in the Pancreas - Results of the Collaborative Research Center 518 (SFB 518) at the University of Ulm Pancreas 2011 40(4):489-502

16. A Kleger, S Liebau, Q Lin, **G von Wichert**, T Seufferlein The impact of bioactive lipids on cardiovascular development. Stem Cells Int. 2011:916180

17. MW Kühn, R Blagieva, D Beha, M Hänle, F Reister, D Henne-Bruns, C Pilcher, BO Böhm, **G von Wichert** A 31-year-old pregnant woman with refractory hypercalcemia. Internist (Berl). 2012; 53(12):1490-5.

18. P von Wichert, P Barth, **G von Wichert** Tracheal and bronchial involvement in colitis ulcerosa - a colo-bronchitic syndrome? A case report and some additional considerations. Ger Med Sci. 2015 Mar 30;13:Doc 03.

19. **G von Wichert**, L Stiedenroth, F Jacobsen, H Kopdag, K Rückert, U Nahrstedt Das Magenkarzinom - Aktuelle Therapiekonzepte Hamburger Ärzteblatt 06-2017; 12-16

20. T Werner, L Stiedenroth, S Jaganjac, **G von Wichert** Das hepatozelluläre Karzinom - Aktuelle Therapiekonzepte Hamburger Ärzteblatt 04-2018; 14-18

### 2.3. Buchbeiträge

1. **G von Wichert**, G. Adler and T. Seufferlein, The organized anarchy: Signal transduction mechanisms regulating pancreatic cancer growth 2001, Recent Res. Devel. Cancer 3: 337-354

2. **G von Wichert**, G. Adler and T. Seufferlein, Onkologie in "Medizinische Prävention und Gesundheitsförderung" (J. Haisch (Hrsg.)); Hans Huber Verlag 2006

3. **G von Wichert**, T. Seufferlein, Medikamentöse Therapie des Pankreaskarzinoms in "Innere Medizin" (Lehnert (Hrsg.)); Springer Verlag 2015

### 2.4. Herausgebortätigkeit

T Seufferlein, V. Kächele, **G von Wichert**, G. Adler (Hrsgb.) Gastrointestinale Onkologie - Aktuelle Diagnostik und Therapie. Deutscher Apotheker Verlag. 2008